Neupulse secures more funding to advance world’s first wearable device to tackle Tourette Syndrome

Neupulse has secured more funding to advance the world’s first wearable device aimed at tackling Tourette Syndrome (TS) and other tic disorders towards commercialisation through the Midlands Engine Investment Fund II, facilitated by appointed fund manager for the East and South East Midlands, Mercia Ventures.

This follows a £2.5M investment earlier this year and brings the total the company has raised to date to almost £4.5m.

Paul Cable CEO of Neupulse said:

“This funding from Midlands Engine Investment Fund II will take us one step further towards our mission to roll out our device and give new hope to people with Tourette's. Having Mercia Ventures on board as a partner provides additional value, given its expertise in backing businesses that are developing new products and helping them gain entry to the US market.”

Sandy Reid of Mercia Ventures added:

"Tourette Syndrome is believed to affect up to 2 per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions.

Neupulse's device offers a genuine alternative. This funding will help the company to bring it to market and transform lives.”